Építés alatt – nem éles oldal
Belépés
Befejeződött3. fázis

Study to Compare Efficacy Safety and Immunogenicity of ADL-018 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria

A legfontosabb adatok

Ki végzi
Kashiv BioSciences, LLC
Hol
Brandon, Brooksville, Miami Lakes és West Lafayette (Egyesült Államok)Mind a 4 helyszín megnézéseMég 2 másik országban, 2 helyszínen
Azonosító
Állapot
Befejeződött
Fázis
3. fázis
Résztvevők
600 fő vett részt
Kezdés
2023. aug. 15.
Befejezés
2024. dec. 31.
A vizsgálat típusa
Beavatkozással járó, 10 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Omalizumab Injection
  • Xolair Prefilled Syringe
A regiszteradat frissítve
2025. február 5.

Ki vehet részt

Életkor
18 év – 75 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 26 feltétel megnézéseKevesebb

Ki vehet részt

  • Capable of providing written informed consent, adhering to all visit schedules, and meeting study requirements
  • Male or female patients 18 to 75 years of age (both inclusive) at the time of screening
  • Diagnosis of CIU refractory to H1 antihistamines at the time of randomization, as defined by all of the following:; CIU diagnosis for at least 6 months; Must have been on an approved H1 antihistamine for CIU for at least 3 consecutive days immediately prior to the Day -14 screening visit and must document current use on the day of initial screening; Presence of itch and hives for ≥ 8 consecutive weeks at any time prior to enrollment despite current use of H1 antihistamine treatment; In-clinic UAS ≥ 4 on at least 1 of the screening visit days (Day -14, Day -7, or Day 1); UAS7 (range 0-42) ≥ 16 and itch component of UAS7 (range 0-21) ≥ 8 during 7 days prior to randomization
  • Willing and able to complete a daily symptom diary for the duration of the study and must not have any missing diary entries in the 7 days prior to randomization
  • Females of childbearing potential must be willing to use acceptable contraceptive methods throughout the study and for 6 months thereafter
  • Females of non-childbearing potential must have undergone sterilization procedures, at least 6 months prior to the first dose or be postmenopausal with amenorrhea for at least 1 year prior to the first dose and follicle stimulating hormone serum levels consistent with postmenopausal status

Ki nem vehet részt

  • Participation in a clinical trial involving the administration of an investigational drug or marketed drug within 30 days prior to initial dosing (90 days for biologics)
  • Previous treatment with omalizumab within a year prior to screening
  • Routine doses of the following medications within 10 days prior to screening: Systemic or cutaneous (topical) corticosteroids (prescription or over the counter), hydroxychloroquine, methotrexate, cyclosporine, or cyclophosphamide or investigational agents such as benralizumab or dupilumab etc
  • IVIG ( Intravenous immune globulin) or plasmapheresis within 90 days prior to screening
  • Regular (daily/every other day) doxepin (oral) use within 14 days prior to screening
  • Any H2 antihistamine use within 7 days prior to screening
  • Any LTRA (Leukotriene receptor antagonists such as montelukast or zafirlukast) within 10 to 14 days prior to screening
  • Evidence of current drug or alcohol abuse
  • Evidence of parasitic infection
  • Atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus, or any other skin disease associated with itch
  • Patients with current malignancy, history of malignancy, or currently under work-up for suspected malignancy except non-melanoma skin cancer that has been treated or excised and is considered resolved
  • Hypersensitivity to omalizumab or any component of the formulation
  • History of anaphylactic shock
  • Presence of clinically significant cardiovascular, neurological, psychiatric, metabolic, or other pathological conditions that could interfere with the interpretation of the study results and/or compromise the safety of the patients
  • Positive test for hepatitis B, hepatitis C, or HIV
  • History of any clinically significant disease or condition that, in the opinion of the Principal Investigator (PI)/designee, would render them unsuitable for inclusion in the study
  • Medical examination or laboratory findings that suggest the possibility of decompensation of co-existing conditions for the duration of the study
  • Clearly defined underlying etiology for chronic urticarias other than CIU
  • Females with positive pregnancy tests at screening or any other visit
  • Females who are breastfeeding or lactating

Helyszínek itt: Egyesült Államok

Még 2 másik országban, 2 helyszínen

  • True Blue Clinical ResearchBrandon, Egyesült Államok
  • Access Research InstituteBrooksville, Egyesült Államok
  • San Marcus Research Clinic, Inc.Miami Lakes, Egyesült Államok
  • Options Research GroupWest Lafayette, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of the study is to compare the efficacy, safety, tolerability, and immunogenicity of ADL-018 compared to XOLAIR in patients with Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) who remain symptomatic on H1 antihistamine treatment

A vizsgálat 10 csoportja

  • ADL-018 300 mg Main Treatment periodA vizsgált kezelés

    ADL-018 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 0, 4, 8

    Kezelés: Omalizumab Injection

  • Xolair-300 mg Main Treatment PeriodMár használt kezelés, összehasonlításként

    XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 0, 4, 8

    Kezelés: Xolair Prefilled Syringe

  • ADL-018 150 mg Main Treatment periodA vizsgált kezelés

    ADL-018 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 0, 4, 8

    Kezelés: Omalizumab Injection

  • Xolair-150 mg Main Treatment PeriodMár használt kezelés, összehasonlításként

    XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 0, 4, 8

    Kezelés: Xolair Prefilled Syringe

  • ADL-018 300 mg Main / ADL-018 300 mg Transition PeriodA vizsgált kezelés

    ADL-018 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to ADL-018 300 mg in the Main Treatment period.

    Kezelés: Omalizumab Injection

  • Xolair-300 mg Main / ADL-018 300 mg Transition PeriodA vizsgált kezelés

    ADL-018 (Omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to Xolair-300 mg in the main treatment period.

    Kezelés: Omalizumab Injection és Xolair Prefilled Syringe

  • Xolair-300 mg Main / Xolair-300 mg Transition PeriodMár használt kezelés, összehasonlításként

    XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered twice (total dosage 300 mg) at week 12,16,20 in patients that were randomized to Xolair-300 mg in the main treatment period.

    Kezelés: Xolair Prefilled Syringe

  • ADL-018 150 mg Main / ADL-018 150 mg Transition PeriodA vizsgált kezelés

    ADL-018 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to ADL-018150 mg in the main treatment period.

    Kezelés: Omalizumab Injection

  • Xolair-150 mg Main / ADL-018150 mg Transition PeriodA vizsgált kezelés

    ADL-018 (Omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to XOLAIR-150 mg in the main treatment period.

    Kezelés: Omalizumab Injection és Xolair Prefilled Syringe

  • Xolair-150 mg Main / Xolair-150 mg Transition PeriodMár használt kezelés, összehasonlításként

    XOLAIR (omalizumab) injection 150 mg/mL pre-filled syringe administered with one placebo injection at week 12,16,20 in patients that were randomized to XOLAIR -150 mg in the main treatment period.

    Kezelés: Xolair Prefilled Syringe

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Randomized, Multicenter, Double-Blind, 4-Arm, Parallel-Group, Active Controlled, Phase 3 Study to Compare Efficacy, Safety and Immunogenicity of ADL-018 150 mg and 300 mg With US-Licensed Xolair® 150 mg and 300 mg Administered Through Subcutaneous Route Every 4 Weeks in Patients With Chronic Idiopathic Urticaria (CIU) Who Remained Symptomatic Despite Treatment With Approved Doses of H1 Antihistamines
A regiszteradat frissítve
2025. február 5.